Please use this identifier to cite or link to this item:
Title: Tracking Drug-Induced Epithelial-Mesenchymal Transition in Breast Cancer by a Microfluidic Surface-Enhanced Raman Spectroscopy Immunoassay.
Austin Authors: Zhang, Zhen;Wang, Jing;Shanmugasundaram, Karthik Balaji;Yeo, Belinda ;Möller, Andreas;Wuethrich, Alain;Lin, Lynlee L;Trau, Matt
Affiliation: Dermatology Research Centre, University of Queensland Diamantina Institute, University of Queensland, Brisbane, QLD, 4102, Australia
Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, 4072, Australia
School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, 4072, Australia
Issue Date: Apr-2020
Date: 2020-03-05
Publication information: Small (Weinheim an der Bergstrasse, Germany) 2020; 16(13): e1905614
Abstract: Epithelial-mesenchymal transition (EMT) is a primary mechanism for cancer metastasis. Detecting the activation of EMT can potentially convey signs of metastasis to guide treatment management and improve patient survival. One of the classic signatures of EMT is characterized by dynamic changes in cellular expression levels of E-cadherin and N-cadherin, whose soluble active fragments have recently been reported to be biomarkers for cancer diagnosis and prognosis. Herein, a microfluidic immunoassay (termed "SERS immunoassay") based on sensitive and simultaneous detection of soluble E-cadherin (sE-cadherin) and soluble N-cadherin (sN-cadherin) for EMT monitoring in patients' plasma is presented. The SERS immunoassay integrates in situ nanomixing and surface-enhanced Raman scattering readout to enable accurate detection of sE-cadherin and sN-cadherin from as low as 10 cells mL-1 . This assay enables tracking of a concurrent decrease in sE-cadherin and increase in sN-cadherin in breast cancer cells undergoing drug-induced mesenchymal transformation. The clinical potential of the SERS immunoassay is further demonstrated by successful detection of sE-cadherin and sN-cadherin in metastatic stage IV breast cancer patient plasma samples. The SERS immunoassay can potentially sense the activation of EMT to provide early indications of cancer invasions or metastasis.
DOI: 10.1002/smll.201905614
ORCID: 0000-0001-6080-7998
Journal: Small (Weinheim an der Bergstrasse, Germany)
PubMed URL: 32141228
Type: Journal Article
Subjects: SERS immunoassays
breast cancer
cancer metastasis
epithelial-mesenchymal transition
soluble proteins
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 22, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.